Drugs interfering with mitochondrial disorders

Drug and Chemical Toxicology

Volumn 33, Issue 2, 2010, Pages 138-151

  Finsterer, Josef ^a   Segall, Liane ^a  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

Adverse reaction; Mitochondria; Myopathy; Neuromuscular disorder; Side effects; Therapy; Treatment

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMIODARONE; ANALGESIC AGENT; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; BARBITURIC ACID DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE; CARBAMAZEPINE; CORTICOSTEROID; FENTANYL; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INHALATION ANESTHETIC AGENT; INTRAVENOUS ANESTHETIC AGENT; LOCAL ANESTHETIC AGENT; MUSCLE RELAXANT AGENT; NEUROLEPTIC AGENT; OXCARBAZEPINE; PHENYTOIN; PROPOFOL; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNINDEXED DRUG; VALPROIC ACID; VITAMIN;

APNEA; ASYSTOLE; BRADYCARDIA; BRAIN DISEASE; CORTICOSTEROID INDUCED MYOPATHY; DIETARY INTAKE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FOLIC ACID DEFICIENCY; HEART ATRIUM FIBRILLATION; HEART BUNDLE BRANCH BLOCK; HEART FAILURE; HEART VENTRICLE TACHYCARDIA; HEPATOMEGALY; HUMAN; HYPERAMMONEMIA; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; INTESTINE PSEUDOOBSTRUCTION; KIDNEY FAILURE; LACTIC ACIDOSIS; LOW DRUG DOSE; LUNG FIBROSIS; METABOLIC ACIDOSIS; MICROVESICULAR STEATOSIS; MITOCHONDRIAL GENETICS; MITOCHONDRIAL HEPATOPATHY; MUSCLE CRAMP; MUSCLE WEAKNESS; MYOCLONUS EPILEPSY; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PHYSIOTHERAPY; PROGRESSIVE MUSCULAR ATROPHY; PROPOFOL INFUSION SYNDROME; REVIEW; REYE LIKE SYNDROME; REYE SYNDROME; RHABDOMYOLYSIS; SEIZURE; STEATOSIS; SUPRAVENTRICULAR TACHYCARDIA; SURGICAL TECHNIQUE;

ANIMALS; HUMANS; MITOCHONDRIA; MITOCHONDRIAL DISEASES; PHARMACEUTICAL PREPARATIONS;

EID: 77949878549     PISSN: 01480545     EISSN: 15256014     Source Type: Journal    
DOI: 10.3109/01480540903207076     Document Type: Review

References (129)

1. Ahn, M. S., Sims, K. B., Frazier, J. A. (2005). Risperidone-induced psychosis and depression in a child with a mitochondrial disorder. J Child Adolesc Psychopharmacol 15:520-525.
2. 2+ overload and ROS release. Cardiovasc Res 77:406-415.
3. Aleisa, A. M., Al-Majed, A. A., Al-Yahya, A. A., Al-Rejaie, S. S., Bakheet, S. A., Al-Shabanah, O. A., et al. (2007). Reversal of cisplatin-induced carnitine defciency and energy starvation by propionyl-L-carnitine in rat kidney tissues. Clin Exp Pharmacol Physiol 34:1252-1259.
4. Allen, R. J., DiMauro, S., Coulter, D. L., Papadimitriou, A., Rothenberg, S. P. (1983). Kearns-Sayre syndrome with reduced plasma and cerebrospinal fuid folate. Ann Neurol 13:679-682.
5. Almawi, W. Y., Melemedjian, O. K., Jaoude, M. M. (2004). On the link between Bcl-2 family proteins and glucocorticoid-induced apoptosis. J Leukoc Biol 76:7-14.
6. Anderson, C. M., Norquist, B. A., Vesce, S., Nicholls, D. G., Soine, W. H., Duan, S., et al. (2002). Barbiturates induce mitochondrial depolarization and potentiate excitotoxic neuronal death. J Neurosci 22:9203-9209.
7. Angelini, C., Federico, A., Reichmann, H., Lombes, A., Chinnery, P., Turnbull, D. (2006). Task force guidelines handbook: EFNS guidelines on diagnosis and management of fatty acid mitochondrial disorders. Eur J Neurol 13:923-929.
8. Aouad, M. T., Gerges, F. J., Baraka, A. S. (2005). Resistance to cis-atracurium in a patient with MELAS syndrome. Paediatr Anaesth 15:1124-1127.
9. Arenas, J, Fernández-Moreno, MA, Molina, JA, Fernández, V, del Hoyo, P, Campos, Y, et al. (2003). Myoglobinuria and COX defciency in a patient taking cerivastatin and gemfbrozil. Neurology 60:124-126.
10. Artuch, R., Aracil, A., Mas, A., et al. (2002). Friedreich's ataxia: idebenone treatment in early stage patients. Neuropediatrics 33:190-193.
11. Aure, K., Benoist, J. F., Ogier de Baulny, H., Romero, N. B., Rigal, O., Lombes, A. (2004). Progression despite replacement of a myopathic form of coenzyme Q10 defect. Neurology 63:727-729.
12. Balijepalli, S., Kenchappa, R. S., Boyd, M. R., Ravindranath, V. (2001). Protein thiol oxidation by haloperidol results in inhibition of mitochondrial complex I in brain regions: comparison with atypical antipsychotics. Neurochem Int 38:425-435.
13. Barisic, N., Bernert, G., Ipsiroglu, O., et al. (2002). Efects of oral creatine supplementation in a patient with MELAS phenotype and associated nephropathy. Neuropediatrics 33:157-161.
14. Bastin, J., Aubey, F. , Rötig, A., Munnich, A., Djouadi, F. (2008). Activation of peroxisome proliferator-activated receptor pathway stimulates the mitochondrial respiratory chain and can correct defciencies in patients' cells lacking its components. J Clin Endocrinol Metab 93:1433-1441.
15. Beekmann, S. E., Gilbert, D. N., Polgreen, P. M.; the IDSA Emerging Infections Network. (2008). Toxicity of extended courses of linezolid: results of an Infectious Diseases Society of America Emerging Infections Network survey. Diagn Microbiol Infect Dis (In press).
16. Bolt, M. W., Card, J. W., Racz, W. J., Brien, J. F., Massey, T. E. (2001). Disruption of mitochondrial function and cellular ATP levels by amiodarone and N-desethylamiodarone in initiation of amiodarone-induced pulmonary cytotoxicity. J Pharmacol Exp Ter 298:1280-1289.
17. Breucking, E., Mortier, W., Lampert, R., Brandt, L. (1993). Anesthesia and intensive therapy for a patient with mito-chondrial myopathy. Anaesthesist 42:719-723.
18. Briere, J. J., Schlemmer, D., Chretien, D., Rustin, P. (2004). Quinone analogues regulate mitochondrial substrate competitive oxidation. Biochem Biophys Res Commun 316:1138-1142.
19. Brunmair, B., Lest, A., Staniek, K., Gras, F. , Scharf, N., Roden, M., et al. (2004). Fenofbrate impairs rat mitochondrial function by inhibition of respiratory complex I. J Pharmacol Exp Ter 311:109-114.
20. Brunmair, B., Staniek, K., Gras, F., Scharf, N., Althaym, A., Clara, R., et al. (2004). Tiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes 53:1052-1059.
21. Cai, Y., Nelson, B. D., Li, R., Luciakova, K., dePierre, J. W. (1996). Tyromimetic action of the peroxisome proliferators clof-brate, perfuorooctanoic acid, and acetylsalicylic acid includes changes in mRNA levels for certain genes involved in mitochondrial biogenesis. Arch Biochem Biophys 325:107-112.
22. Carvalho, C., Correia, S., Santos, M. S., Seiça, R., Oliveira, C. R., Moreira, P. I. (2008). Metformin promotes isolated rat liver mitochondria impairment. Mol Cell Biochem 308:75-83.
23. Casademont, J., Garrabou, G., Miró, O., López, S., Pons, A., Bernardo, M., et al. (2007). Neuroleptic treatment efect on mitochondrial electron transport chain: peripheral blood mononuclear cells analysis in psychotic patients. J Clin Psychopharmacol 27:284-288.
24. Cheam, E. W., Critchley, L. A. (1998). Anesthesia for a child with complex I respiratory chain enzyme defciency. J Clin Anesth 10:524-527.
25. Chen, P. S., Wang, C. C., Bortner, C. D., Peng, G. S., Wu, X., Pang, H., et al. (2007). Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neu-rotoxicity. Neuroscience 149:203-212.
26. Chen, Q., Moghaddas, S., Hoppel, C. L., Lesnefsky, E. J. (2006). Reversible blockade of electron transport during ischemia protects mitochondria and decreases myocar-dial injury following reperfusion. J Pharmacol Exp Ter 319:1405-1412.
27. Cherry, C. L., Lala, L., Wesselingh, S. L. (2005). Mitochondrial toxicity of nucleoside analogues: mechanism, monitoring, and management. Sex Health 2:1-11.
28. Chiyonobu, T., Noda, R., Yoshida, M., Fujiki, A., Ishii, R., Nukina, S., et al. (2008). Intestinal pseudo-obstruction in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) associated with phenytoin therapy. Brain Dev 30:430-433.
29. Choi, C., Sunwoo, I. N., Kim, H. S., Kim, D. I. (2000). Transient improvement of pyruvate metabolism after coenzyme Q therapy in Kearns-Sayre syndrome: MRS study. Yonsei Med J 41:676-679.
30. Cocco, T., Cutecchia, G., Montedoro, G., Lorusso, M. (2002). Te antihypertensive drug, carvedilol, inhibits the activity of mitochondrial NADH-ubiquinone oxidoreductase. J Bioenerg Biomembr 34:251-258.
31. Cooper, J. M., Schapira, A. H. (2003). Friedreich's ataxia: disease mechanisms, antioxidant, and coenzyme Q10 therapy. Biofactors 18:163-171.
32. Cushing, H. (1932). Te basophil adenomas of the pituitary body and their clinical manifestations. John Hopkins Med J 50:137.
33. Devi, B. G., Chan, A. W. (1997). Impairment of mitochondrial respiration and electron transport chain enzymes during cocaine-induced hepatic injury. Life Sci 60:849-855.
34. Devin, A., Nogueira, V. , Avéret, N., Leverve, X., Rigoulet, M. (2006). Profound efects of the general anesthetic etomidate on oxidative phosphorylation without efects on their yield. J Bioenerg Biomembr 38:137-142.
35. dos Santos, N. A., Martins, N. M., Curti, C., Pires Bianchi, Mde L., dos Santos, A. C. (2007). Dimethylthiourea protects against mitochondrial oxidative damage induced by cisplatin in liver of rats. Chem Biol Interact 170:177-186.
36. El-Mir, M. Y., Detaille, D., R?-Villanueva, G., Delgado-Esteban, M., Guigas, B., Attia, S., et al. (2008). Neuroprotective role of antidiabetic drug metformin against apoptotic cell death in primary cortical neurons. J Mol Neurosci 34:77-87.
37. Farag, E., Argalious, M., Narouze, S., DeBoer, G. E., Tome, J. (2002). Te anesthetic management of ventricular septal defect (VSD) repair in a child with mitochondrial cytopathy. Can J Anaesth 49:958-962.
38. Finsterer, J., Gelpi, E. (2006). Mitochondrial disorder aggravated by propranolol. South Med J 99:768-771.
39. Finsterer, J., Zuntner, G. (2005). Rhabdomyolysis from simvasta-tin triggered by infection and muscle exertion. South Med J 98:827-829.
40. Finsterer, J., Jarius, C., Eichberger, H. (2001). Phenotype variability in 130 adult patients with respiratory chain disorders. J Inherit Metab Dis 24:560-576.
41. Finsterer, J., Haberler, C., Schmiedel, J. (2005). Deterioration of Kearns-Sayre syndrome following articaine administration for local anesthesia. Clin Neuropharmacol 28:148-149.
42. Finsterer, J., Harbo, H. F., Baets, J., van Broeckhoven, C., Di Donato, S., Fontaine, B., et al. (2008). EFNS guidelines on the molecular diagnosis of mitochondrial disorders. Eur J Neurol 2009 (In press).
43. Finsterer, J., Stratil, U., Bittner, R., Sporn, P. (1998). Increased sensitivity to rocuronium and atracurium in mitochondrial myopathy. Can J Anaesth 45:781-784.
44. Fodale, V., La Monaca E., (2008). Propofol infusion syndrome: an overview of a perplexing disease. Drug Saf 31:293-303.
45. Fritz, T., Lenz, G., Schorer, R. (1998). Comments on anesthesia procedures in mitochondrial encephalomyopathy. Anasth Intensivther Notfallmed 23:265-270.
46. Fromenty, B., Pessayre, D. (1995). Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ter. 67:101-154.
47. Gioltzoglou, T., Cordivari, C., Lee, P. J., Hanna, M. G., Lees, A. J. (2005). Problems with botulinum toxin treatment in mito-chondrial cytopathy: case report and review of the literature. J Neurol Neurosurg Psychiatry 76:1594-1596.
48. Guigas, B., Detaille, D., Chauvin, C., Batandier, C., De Oliveira, F. , Fontaine, E., et al. (2004). Metformin inhibits mitochondrial permeability transition and cell death: a pharmacological in vitro study. Biochem J 382:877-884.
49. Haas, R., Stumpf, D. A., Parks, J. K., Eguren, L., (1981). Inhibitory efects of sodium valproate on oxidative phosphorylation. Neurology 31:1473-1476.
50. Hanley, P. J., Ray, J., Brandt, U., Daut, J. (2002). Halothane, iso-furane, and sevofurane inhibit NADH:ubiquinone oxi-doreductase (complex I) of cardiac mitochondria. J Physiol 544(Pt 3):687-693.
51. Hara, K., Sata, T., Shigematsu, A. (2004). Anesthetic management for cardioverter-defbrillator implantation in a patient with Kearns-Sayre syndrome. J Clin Anesth 16:539-541.
52. Heinke, W., Schafranietz, L. (2004). Anaesthesia for combined pancreatic and renal transplantation in a patient with mito-chondrial encepahalomyopathy- case report. Anaesthesiol Reanim 29:87-90.
53. Ishiguro, M., Hashimoto, K., Hayakata, Y., Fukunaga, S., Seo, N. (2006). Prolonged respiratory depression after fenta-nyl administration in a patient with mitochondrial encepha-lomyopathy. Masui 55:73-75.
54. Itaya, K., Takahata, O., Mamiya, K., Saito, T., Tamakawa, S., Akama, Y., et al. (1995). Anesthetic management of two patients with mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS). Masui 44:710-712.
55. Johnson, T. E., Zhang, X, Shi, S., Umbenhauer, D. R. (2005). Statins and PPARalpha agonists induce myotoxicity in differentiated rat skeletal muscle cultures but do not exhibit synergy with co-treatment. Toxicol Appl Pharmacol 208:210-221.
56. Kam, P. C., Cardone, D. (2007). Propofol infusion syndrome. Anaesthesia 62:690-701.
57. Kayihan, N., Nennesmo, I., Ericzon, B. G., Németh, A. (2000). Fatal deterioration of neurological disease after orthotopic liver transplantation for valproic acid-induced liver damage. Pediatr Transpl 4:211-214.
58. Kim, J. Y., Lee, H. W. (2007). Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug mono-therapy. Epilepsia 48:1366-1370.
59. Kirpichnikov, D., McFarlane, S. I., Sowers, J. R. (2002). Metformin: an update. Ann Intern Med 137:25-33.
60. Kitoh, T., Mizuno, K., Otagiri, T., Ichinose, A., Sasao, J., Goto, H. (1995). Anesthetic management for a patient with Kearns-Sayre syndrome. Anesth Analg 80:1240-1242.
61. Klepper, J., Leiendecker, B., Riemann, E., Baumeister, F. A. (2004). Te ketogenic diet in German-speaking countries: update 2003. Klin Padiatr 216:277-285.
62. Klockgether-Radke, A., Henze, T., Braun, U., Kettler, D. (1993). General anesthesia in two patients with mitochondrial myopathy. Anaesthesist 42:111-114.
63. Koga, Y., Akita, Y., Junko, N., Yatsuga, S., Povalko, N., Fukiyama, R., et al. (2006). Endothelial dysfunction in MELAS improved by l-arginine supplementation. Neurology 66:1766-1769.
64. Koga, Y., Akita, Y., Nishioka, J., Yatsuga, S., Povalko, N., Tanabe, Y., et al. (2005). L-arginine improves the symptoms of strokelike episodes in MELAS. Neurology 64:710-712.
65. Kohro, S., Hogan, Q. H., Nakae, Y., Yamakage, M., Bosnjak, Z. J. (2001). Anesthetic efects on mitochondrial ATP-sensitive K channel. Anesthesiology 95:1435-1440.
66. Krähenbühl, S., Brandner, S., Kleinle, S., Liechti, S., Straumann, D. (2000). Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. Liver 20:346-348.
67. Kushikata, T., Yatsu, Y., Kubota, T., Matsuki, A. (2004). Total intravenous anesthesia with propofol, ketamine, and fentanyl (PFK) for a patient with mitochondrial myopathy. Masui 53:178-180.
68. Laforêt, P., Nicolino, M., Eymard, B. (2007). New approaches for the treatment of metabolic myopathies. Rev Neurol (Paris) 163:930-935.
69. Lam, C. W., Lau, C. H., Williams, J. C., Chan, Y. W., Wong, L. J. (1997). Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) triggered by val-proate therapy. Eur J Pediatr 156:562-564
70. Langsjoen, P. H., Langsjoen, A., Willis, R., Folkers, K. (1997). Treatment of hypertrophic cardiomyopathy with coenzyme Q10. Mol Aspects Med 18(Suppl):S145-S151.
71. Lechner, J., Malloth, N., Seppi, T., Beer, B., Jennings, P., Pfaller, W. (2008). IFN-alpha induces barrier destabilization and apop-tosis in renal proximal tubular epithelium. Am J Physiol Cell Physiol 294:C153-C160.
72. Ledl, M., Hohenecker, J., Francesconi, C., Roots, I., Bauer, M. F. , Roden, M. (2005). Acute myopathy in a type 2 diabetic patient on combination therapy with metformin, fenofbrate, and rosiglitazone. Diabetologia 48:1996-1998.
73. Létuvé, S., Druilhe, A., Grandsaigne, M., Aubier, M., Pretolani, M. (2002). Critical role of mitochondria, but not caspases, during glucocorticosteroid-induced human eosinophil apopto-sis. Am J Respir Cell Mol Biol 26:565-571.
74. Lin, C. M., Tajeb, P. (2007). Valproic acid aggravates epilepsy due to MELAS in a patient with an A3243G mutation of mito-chondrial DNA. Metab Brain Dis 22:105-109.
75. Looareesuwan, S., Chulay, J. D., Canfeld, C. J., Hutchinson, D. B. (1999). Malarone (atovaquone and proguanil hydrochlo-ride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group. Am J Trop Med Hyg 60:533-541.
76. Luís, P. B., Ruiter, J. P., Aires, C. C., Soveral, G., de Almeida, I. T., Duran, M., et al. (2007). Valproic acid metabolites inhibit dihydrolipoyl dehydrogenase activity leading to impaired 2-oxoglutarate-driven oxidative phosphorylation. Biochim Biophys Acta 1767:1126-1133.
77. Maeda, Y., Mitsumizo, S., Yoshida, M., Nakashima, M., Harano, K., Totoki, T. (2001). Perioperative administration of bicarbonated solution to a patient with mitochondrial encephalomyopathy. Masui 50:299-303.
78. Mancuso, M., Galli, R., Pizzanelli, C., Filosto, M., Siciliano, G., Murri, L. (2006). Antimyoclonic efect of levetiracetam in MERRF syndrome. J Neurol Sci 243:97-99.
79. Marriage, B., Clandinin, M. T., Glerum, D. M. (2003). Nutritional cofactor treatment in mitochondrial disorders. J Am Diet Assoc 103:1029-1038.
80. Matsuno, S., Hashimoto, H., Matsuki, A. (1994). Neuroleptanesthesia for a patient with mitochondrial encephalomyopathy. Masui 43:1038-1040.
81. McFarland, R., Hudson, G., Taylor, R. W., Green, S. H., Hodges, S., McKiernan, P. J., et al. (2008). Reversible valproate hepato-toxicity due to mutations in mitochondrial DNA polymerase gamma (POLG1). Arch Dis Child 93:151-153.
82. Mitra, M. S., Donthamsetty, S., White, B., Mehendale, H. M. (2008). High-fat-diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity. Toxicol Appl Pharmacol 231:413-422.
83. Modica-Napolitano, J. S., Lagace, C. J., Brennan, W. A., Aprille, J. R. (2003). Diferential efects of typical and atypical neuroleptics on mitochondrial function in vitro. Arch Pharm Res 26:951-959.
84. Monros, E., Pineda, M. (2002). Friedreich's ataxia: ide-benone treatment in early stage patients. Neuropediatrics 33:190-193.
85. Mottin, S., Laporte, P. , Cespuglio, R. (2003). Inhibition of NADH oxidation by chloramphenicol in the freely moving rat measured by picosecond time-resolved emission spectroscopy. J Neurochem 84:633-642.
86. Mythili, Y., Sudharsan, P. T., Varalakshmi, P. (2005). dl-alpha-lipoic acid ameliorates cyclophosphamide induced cardiac mitochondrial injury. Toxicology 215:108-114.
87. Naguib, M., el-Dawlatly, A. A., Ashour, M., al-Bunyan, M. (1996). Sensitivity to mivacurium in a patient with mitochondrial myopathy. Anesthesiology 84:1506-1509.
88. Napolitano, A., Salvetti, S., Vista, M., Lombardi, V. , Siciliano, G., Giraldi, C. (2000). Long-term treatment with idebenone and ribofavin in a patient with MELAS. Neurol Sci 21 (Suppl 5):S981-S982.
89. Nissim, I., Horyn, O., Daikhin, Y., Nissim, I., Luhovyy, B., Phillips, P. C., et al. (2006). Ifosfamide-induced neph-rotoxicity: mechanism and prevention. Cancer Res 66:7824-7831.
90. Nouette-Gaulain, K., Sirvent, P., Canal-Rafn, M., Morau, D., Malgat, M., Molimard, M., et al. (2007). Efects of intermittent femoral nerve injections of bupivacaine, lev-obupivacaine, and ropivacaine on mitochondrial energy metabolism and intracellular calcium homeostasis in rat psoas muscle. Anesthesiology 106:1026-1034.
91. Novalija, E., Kevin, L. G., Eells, J. T., Henry, M. M., Stowe, D. F. (2003). Anesthetic preconditioning improves adenosine triphosphate synthesis and reduces reactive oxygen species formation in mitochondria after ischemia by a redox dependent mechanism. Anesthesiology 98:1155-1163.
92. Oliveira, P. J., Gonçalves, L., Monteiro, P., Providencia, L. A., Moreno, A. J. (2005). Are the antioxidant properties of carvedilol important for the protection of cardiac mitochondria? Curr Vasc Pharmacol 3:147-158.
93. Ortiz-Gómez, J. R., Souto-Ferro, J. M. (2006). Anesthesia for a patient with mitochondrial respiratory chain complex III defciency. Rev Esp Anestesiol Reanim 53:575-579.
94. Oshima, Y., Kuroda, Y., Kunishige, M., Matsumoto, T., Mitsui, T. (2004). Oxidative stress-associated mitochondrial dysfunction in corticosteroid-treated muscle cells. Muscle Nerve 30:49-54.
95. Päivä, H., Telen, K. M., Van Coster, R., Smet, J., De Paepe, B., Mattila, K. M., et al. (2005). High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ter 78:60-68.
96. Pearce, R. J., Duchen, M. R. (1995). Electrophysiological and metabolic efects of a convulsant barbiturate on dissociated mouse primary sensory neurons. J Physiol 483:407-420.
97. Perronne, C. (2006). Antiviral hepatitis and antiretroviral drug interactions. J Hepatol 44(Suppl):S119-S125.
98. Pessayre, D., Mansouri, A., Haouzi, D., Fromenty, B. (1999). Hepatotoxicity due to mitochondrial dysfunction. Cell Biol Toxicol 15:367-373.
99. Rasmussen, M., Sanengen, T., Skullerud, K., Kvittingen, E. A., Skjeldal, O. H. (2000). Evidence that Alpers-Huttenlocher syndrome could be a mitochondrial disease. J Child Neurol 15:473-477.
100. Reeve, J. L., Szegezdi, E., Logue, S. E., Chonghaile, T. N., O'Brien, T., Ritter, T., et al. (2007). Distinct mechanisms of cardiomyocyte apoptosis induced by doxorubicin and hypoxia converge on mitochondria and are inhibited by Bcl-xL. J Cell Mol Med 11:509-520.
101. Sabaté, S., Ferrándiz, M., Paniagua, P. , Villamor, J. M., Vilanova, F. , Villar-Landeira, J. M. (1996). Anesthesia in Kearns-Sayre syndrome (mitochondrial myopathy). Rev Esp Anestesiol Reanim 43:255-257.
102. Saitoh, A., Haas, R. H., Naviaux, R. K., Salva, N. G., Wong, J. K., Spector, S. A. (2008). Impact of nucleoside reverse tran-scriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells. Antimicrob Agents Chemother 52:2825-2830.
103. Scatena, R., Bottoni, P., Martorana, G. E., Ferrari, F., De Sole, P., Rossi, C., et al. (2004). Mitochondrial respiratory chain dysfunction, a non-receptor-mediated efect of synthetic PPAR-ligands: biochemical and pharmacological implications. Biochem Biophys Res Commun 319:967-973.
104. Schols, L., Meyer, C. H., Schmid, G., Wilhelms, I., Przuntek, H. (2004). Terapeutic strategies in Friedreich's ataxia. J Neural Transm (Suppl):135-145.
105. Schols, L., Zange, J., Abele, M., Schillings, M., Skipka, G., Kuntz-Hehner, S., et al. (2005). L-carnitine and creatine in Friedreich's ataxia. A randomized, placebo-controlled crossover trial. J Neural Transm 112:789-796.
106. Scruggs, E. R., Dirks Naylor, A. J. (2008). Mechanisms of zidovudine-induced mitochondrial toxicity and myopathy. Pharmacology 82:83-88.
107. 2 myo-cardial cells. Biochim Biophys Acta 1767:222-232.
108. Shapira, Y., Cederbaum, S. D., Cancilla, P. A., Nielsen, D., Lippe, B. M. (1975). Familial poliodystrophy, mitochondrial myopathy, and lactate acidemia. Neurology 25:614-621.
109. Sharma, A. D., Erb, T., Schulman, S. R., Sreeram, G., Slaughter, T. F. (2001). Anaesthetic considerations for a child with combined Prader-Willi syndrome and mitochondrial myopathy. Paediatr Anaesth 11:488-490.
110. Shenkman, Z., Krichevski, I., Elpeleg, O. N., Joseph, A., Kadari, A. (1997). Anaesthetic management of a patient with Leigh's syndrome. Can J Anaesth 44:1091-1095.
111. Shibukawa, K., Kawamata, M., Seki, S., Narimatsu, E., Namiki, A. (2002). Te use of propofol combined with nitrous oxide and fentanyl in anesthetic management of a patient with mito-chondrial encephalomyopathy. Masui 51:888-891.
112. Short, T. G., Young, Y. (2003). Toxicity of intravenous anaesthetics. Best Pract Res Clin Anaesthesiol 17:77-89.
113. Silva, M. F., Ruiter, J. P. , Illst, L., Jakobs, C., Duran, M., de Almeida, I. T., et al. (1997). Valproate inhibits the mito-chondrial pyruvate-driven oxidative phosphorylation in vitro. J Inherit Metab Dis 20:397-400.
114. Tatsumi, Y., Nakashima, M., Kitao, T., Kan, K., Tomita, T., Hashimoto, Y., et al. (2006). Anesthetic management of a patient with mitochondrial encephalomyopathy under total intravenous anesthesia. Masui 55:1228-1230.
115. Tiel, A., Ritzka, M., Saur, G. (2001). Anesthesia in mitochon-drial encephalomyopathies. Anaesthesiol Intensivmed Notfallmed Schmerzther 36:437-439.
116. Tompson, V. A, Wahr, J. A. (1997). Anesthetic considerations in patients presenting with mitochondrial myopathy, enceph-alopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome. Anesth Analg 85:1404-1406.
117. Toribe, Y., Tominaga, K., Ogawa, K., Suzuki, Y. (2007). Usefulness of L-arginine infusion for status epilepti-cus in mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. No To Hattatsu 39: 38-43.
118. Toth, G., Morava, E., Bene, J., Selhorst, J. J., Overmars, H., Vreken, P. , et al. (2001). Carnitine-responsive carnitine insufciency in a case of mtDNA 8993TC mutation associated Leigh syndrome. J Inherit Metab Dis 24:421-422.
119. Tovo, P. A., Chiapello, N., Gabiano, C., Zeviani, M., Spada, M. (2005). Zidovudine administration during pregnancy and mitochondrial disease in the ofspring. Antivir Ter 10:697-699.
120. Trost, L. C., Lemasters, J. J. (1996). Te mitochondrial permeability transition: a new pathophysiological mechanism for Reye's syndrome and toxic liver injury. J Pharmacol Exp Ter 278:1000-1005.
121. Tzoulis, C., Engelsen, B. A., Telstad, W., Aasly, J., Zeviani, M., Winterthun, S., et al. (2006). Te spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases. Brain 129:1685-1692.
122. Van Maldergem, L., Trijbels, F. , DiMauro, S., et al. (2002). Coenzyme Q-responsive Leigh's encephalopathy in two sisters. Ann Neurol 52:750-754.
123. Vilela, H., Garcìa-Fernández, J., Parodi, E., Reinoso-Barbero, F. , Durán, P., Gilsanz, F. (2005). Anesthetic management of a patient with MERRF syndrome. Paediatr Anaesth 15:77-79.
124. Vladutiu, G. D. (2008). Genetic predisposition to statin myopa-thy. Curr Opin Rheumatol 20:648-655.
125. Walker, U. A. (2000). Mitochondrial medicine for internists. Med Klin (Munich) 95:689-696.
126. Wisely, N. A., Cook, P. R. (2001). General anaesthesia in a man with mitochondrial myopathy undergoing eye surgery. Eur J Anaesthesiol 18:333-335.
127. Yamamoto, M., Akiyama, C., Aikawa, H. (1990). D-penicillamine-induced copper defciency in suckling mice: neurological abnormalities and brain mitochondrial enzyme activities. Brain Res Dev Brain Res 55:51-55.
128. Yunis, A. A. (1989). Chloramphenicol toxicity: 25 years of research. Am J Med 87:44N-48N.
129. Zaugg, M., Lucchinetti, E., Spahn, D. R., Pasch, T., Garcia, C., Schaub, M. C. (2002). Diferential efects of anesthetics on mitochondrial K(ATP) channel activity and cardiomyocyte protection. Anesthesiology 97:15-23.